Intrinsiqq
ConvaTec logo

ConvaTec Quality Score

CTEC.XLON

⊜ Compare
Quality65

Growth remains strong (avg 100/100), but business quality is pulling the composite down (avg 35/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
40.0x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
80/100
24.4x

20–25x, moderate cash flow premium

Revenue Growth
100/100
16.9%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
41.1%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
35.7%

Heavy dilution above 5%

Margin Trend
100/100
+5.2pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
$1.45B

Net debt/FCF of 5.1x, high leverage

2022
$106M
$958M
2023
$98.0M
$1.31B
2024
$65.0M
$1.20B
2025
$68.0M
$1.52B
CashDebt
Return on Capital
40/100
9.9%

8–10%, clearing the bar

Customize WeightsPremiumUpgrade

ConvaTec (CTEC.XLON) quality: score, margins and returns

ConvaTec (CTEC.XLON) scores 65/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 15.8% operating margins and 9.9% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is ConvaTec (CTEC.XLON) a high-quality business?+

ConvaTec scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 15.8% operating margin and a 9.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does ConvaTec's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CTEC.XLON's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where ConvaTec scores well and where it falls behind.

What is ConvaTec's return on invested capital (ROIC)?+

ConvaTec earns about 9.9% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CTEC.XLON's margins and growth on this scorecard to judge durability.

How profitable is ConvaTec?+

ConvaTec runs an operating margin of about 15.8% and a net margin of about 7.2%. Revenue has grown at roughly 4.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on CTEC.XLON: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Peers

Medical Instruments & Supplies · Pick stocks to compare with CTEC.XLON

CompareIntrinsic value
SPI.XLONSpire Healthcare Group plc
£2.49+0.20%56
HIK.XLONHikma Pharmaceuticals
£17.50+0.41%39
GNS.XLONGenus plc
£23.92+0.34%39
FIE.XETRFielmann Group AG
€41.40+2.86%85
DYVOX.XSTODynavox Group AB
€6.47+1.57%63
AMP.XMILAmplifon SpA
€11.67-0.58%27
GXI.XETRGerresheimer AG
€31.98-0.68%11
STMN.XSWXStraumann
CHF 97.66-0.08%55

Held by ETFs

CTEC.XLON is in 36 US ETFs. The largest of them, with CTEC.XLON's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CTEC.XLON

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.